Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review

As part of the update of the International Evidence‐Based Guidelines for the Assessment and Management of polycystic ovary syndrome (PCOS), a systematic review was performed to inform evidence‐based recommendations.

[1]  Denise L. Smith,et al.  A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults , 2022, International journal of molecular sciences.

[2]  A. Latvala,et al.  Systemic hormonal contraception and risk of venous thromboembolism , 2022, Acta obstetricia et gynecologica Scandinavica.

[3]  C. Xing,et al.  Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment , 2022, International journal of women's health.

[4]  A. Wikman,et al.  There is no association between combined oral hormonal contraceptives and depression: a Swedish register‐based cohort study , 2021, BJOG : an international journal of obstetrics and gynaecology.

[5]  D. Dorgham,et al.  Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. , 2021, Journal of drugs in dermatology : JDD.

[6]  K. Kendler,et al.  Oral contraceptive use and risk of suicidal behavior among young women , 2020, Psychological Medicine.

[7]  W. Dodson,et al.  Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. , 2020, Fertility and sterility.

[8]  J. Hiltunen,et al.  Estradiol valerate in COC has more favorable inflammatory profile than synthetic ethinyl estradiol - a randomized trial. , 2020, The Journal of clinical endocrinology and metabolism.

[9]  T. Piltonen,et al.  Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. , 2020, Human reproduction.

[10]  M. Järvelin,et al.  Population-based data at ages 31 and 46 show decreased HRQoL and life satisfaction in women with PCOS symptoms. , 2020, The Journal of clinical endocrinology and metabolism.

[11]  B. Mol,et al.  Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta‐analyses , 2019, Clinical endocrinology.

[12]  M. Urbanek,et al.  Family-based quantitative trait meta-analysis implicates rare noncoding variants in DENND1A in polycystic ovary syndrome. , 2019, The Journal of clinical endocrinology and metabolism.

[13]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[14]  I. Brosens,et al.  Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation , 2018, Expert review of clinical pharmacology.

[15]  L. Redman,et al.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome , 2018, Clinical endocrinology.

[16]  J. Fisher,et al.  Fertility management experiences of women with polycystic ovary syndrome in Australia , 2018, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[17]  L. Tutuncu,et al.  The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. , 2018, Taiwanese journal of obstetrics & gynecology.

[18]  H. Teede,et al.  Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. , 2018, Fertility and sterility.

[19]  R. Chou,et al.  A systematic review and meta‐analysis of venous thrombosis risk among users of combined oral contraception , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  F. Nahidi,et al.  Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis , 2018, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[21]  M. Sammel,et al.  High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis , 2017, Human reproduction.

[22]  L. Kessing,et al.  Association of Hormonal Contraception With Depression. , 2016, JAMA psychiatry.

[23]  G. Morgante,et al.  Hormonal contraceptives: pharmacology tailored to women's health. , 2016, Human reproduction update.

[24]  M. Järvelin,et al.  Weight Gain and Dyslipidemia in Early Adulthood Associate With Polycystic Ovary Syndrome: Prospective Cohort Study. , 2016, The Journal of clinical endocrinology and metabolism.

[25]  R. Cobin,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[26]  W. Dodson,et al.  Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. , 2015, The Journal of clinical endocrinology and metabolism.

[27]  A. Elnashar,et al.  Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period , 2015 .

[28]  A. Algra,et al.  Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. , 2015, The Cochrane database of systematic reviews.

[29]  John A. Barry,et al.  Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis , 2014, Human reproduction update.

[30]  M. Eijkemans,et al.  The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis , 2013, Human reproduction update.

[31]  A. Ruokonen,et al.  Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. , 2012, Human reproduction.

[32]  R. Norman,et al.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. , 2010, Human reproduction.

[33]  D. Guzick,et al.  The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. , 2008, The Journal of clinical endocrinology and metabolism.

[34]  R. Troisi,et al.  Oral contraceptive use and glucose metabolism in a national sample of women in the united states. , 2000, American journal of obstetrics and gynecology.

[35]  H. Teede,et al.  Polycystic ovary syndrome , 2016, Nature Reviews Disease Primers.

[36]  Richard Stevens,et al.  Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. , 2015, The Lancet. Oncology.

[37]  T. Rabe,et al.  Progestogens with Antiandrogenic Properties , 2012, Drugs.

[38]  K. Schulz,et al.  Combination contraceptives: effects on weight. , 2011, The Cochrane database of systematic reviews.

[39]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.